| Literature DB >> 32648087 |
Max J M Silvis1, Evelyne J Demkes2, Aernoud T L Fiolet3, Mirthe Dekker4,5, Lena Bosch3,2, Gerardus P J van Hout3,2, Leo Timmers6, Dominique P V de Kleijn4.
Abstract
Cardiovascular disease (CVD) remains the leading cause of mortality and morbidity worldwide. Atherosclerosis is responsible for the majority of cardiovascular disorders with inflammation as one of its driving processes. The nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasome, responsible for the release of the pro-inflammatory cytokines, interleukin-1β (IL-1β), and interleukin-18 (IL-18), has been studied extensively and showed to play a pivotal role in the progression of atherosclerosis, coronary artery disease (CAD), and myocardial ischemia reperfusion (I/R) injury. Both the NLRP3 inflammasome and its downstream cytokines, IL-1ß and IL-18, could therefore be promising targets in cardiovascular disease. This review summarizes the role of the NLRP3 inflammasome in atherosclerosis, CAD, and myocardial I/R injury. Furthermore, the current therapeutic approaches targeting the NLRP3 inflammasome and its downstream signaling cascade in atherosclerosis, CAD, and myocardial I/R injury are discussed.Entities:
Keywords: Atherosclerosis; Coronary artery disease; Interleukin-18; Interleukin-1β; Ischemia-reperfusion injury; Myocardial infarction; NLRP3 inflammasome
Year: 2020 PMID： 32648087 PMCID： PMC7892681 DOI： 10.1007/s12265-020-10049-w
Source DB: PubMed Journal: J Cardiovasc Transl Res ISSN： 1937-5387 Impact factor: 4.132